Biocon Biologics Refreshes Management
Follows Departure Of Christine Hamacher As CEO
Executive Summary
Biocon has made two key appointments to the management team of Biocon Biologics following a recent change in CEO for the biosimilars business.
You may also be interested in...
Viatris And Biocon Line Up EU Bevacizumab
Viatris’ Mylan has received a positive opinion from the EMA’s CHMP for its bevacizumab biosimilar rival to Avastin under two different names. Meanwhile, Accord has received an endorsement for a generic version of Zytiga.
Biocon And Viatris Scoop EU Insulin Aspart Approval
Biocon and Viatris have landed their second biosimilar insulin approval in Europe, for a rival to Novo Nordisk’s NovoRapid (insulin aspart). Analyst reaction was lukewarm considering the “disappointing” launch of insulin glargine in Europe more than two years ago.
Biocon Biologics CEO Makes Surprise Exit
The CEO of Biocon’s biosimilars subsidiary has unexpectedly departed the role. Management stresses there is no disruption to its "strategic intent", but COVID-19 has "dampened" the arm’s push to reach its aspirational $1bn revenue target by 2022.